首页>投融资
Hemotune
B+轮
Hemotune是一家医疗设备公司，开发治疗性血液净化平台，用于治疗健康疾病。该公司开发了一种基于磁珠的血液净化平台，该平台可以高度选择性和高效地直接从血液中去除大型生物分子，并专注于败血症的免疫学方面，同时处理多种疾病途径，以恢复败血症休克中足够的免疫功能，从而使患者能够通过磁珠获得血液净化治疗。
基本信息
-
公司全称Hemotune AG
-
类型治疗性血液净化平台提供商
-
产业领域医疗器械、治疗设备
-
公司人数15~50人
-
地址Wagistrasse 27 Schlieren 8952, Zurich, Switzerland
-
联系电话
-
邮箱info@hemotune.ch
-
成立时间2017-01-01
投融资
-
2024-03-25B轮1400万瑞士法郎Zürcher Kantonal BankOCCIDENTEFI Lake Geneva VenturesHEMEXBelmondoOVP Venture Partners
-
2024-03-25B+轮1400万瑞士法郎BelmondoEFI Lake Geneva VenturesZürcher KantonalbankOCCIDENTHEMEXOVP Venture Partners
-
2022-04-26B轮725万瑞士法郎HEMEXVP Venture PartnersZürcher Kantonal BankOCCIDENT
-
2022-04-26B轮725万瑞士法郎OCCIDENTVP Venture PartnersHEMEXZürcher Kantonalbank
-
2020-08-12A轮510万瑞士法郎Zürcher Kantonal BankOCCIDENT
-
2020-08-12A轮510万瑞士法郎OCCIDENTZürcher Kantonalbank
- 加载更多
相关投融资企业
C轮
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer yet gentle on patients.In September 2020, Coloplast announced that it has completed a USD 4m (DKK 25m) equity investment in Francis Medical
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
未公开
BetaGlue Therapeutics是一家临床分期肿瘤公司，该公司开发了一种先进的放疗平台，能够对不可切除的实体瘤和手术切缘进行局部靶向治疗，称为YntraDose。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息